CO5590936A2 - Compuesto farmaceutico que contiene sfcyr iib o sfcyr iii - Google Patents
Compuesto farmaceutico que contiene sfcyr iib o sfcyr iiiInfo
- Publication number
- CO5590936A2 CO5590936A2 CO04057552A CO04057552A CO5590936A2 CO 5590936 A2 CO5590936 A2 CO 5590936A2 CO 04057552 A CO04057552 A CO 04057552A CO 04057552 A CO04057552 A CO 04057552A CO 5590936 A2 CO5590936 A2 CO 5590936A2
- Authority
- CO
- Colombia
- Prior art keywords
- sfcyr
- iib
- iii
- fcgammar
- compound containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Compuesto farmacéutico en forma de una solución acuosa, caracterizado porque comprende FcyR IIb y FcyR III producidos en forma recombinante, de sistemas de expresión eucariónticos o especialmente procariónticos en una cantidad de 40 hasta 4000 mg, preferiblemente 100 hasta 1000 mg y una concentración de hasta 50 mg/ml y eventualmente otros excipientes y sustancias auxiliares farmacéuticamente aceptables.2.- Compuesto farmacéutico según la reivindicación 1, caracterizada porque se encuentra en forma de solución inyectable.3.- Compuesto farmacéutico según la reivindicación 1 o 2, caracterizado porque contiene FcyR IIb según SEQ ID NO. 1, o en los terminales N y/o C una forma prolongada de la proteína nativa con secuencias adecuadas preferiblemente según SEQ ID NO. 3.4.- Compuesto farmacéutico según una de las reivindicaciones 1 o 2, caracterizado porque contiene FcyR III, según SEQ ID NO. 2 o en los terminales N y/o C una forma prolongada de la proteína nativa con secuencias adecuadas, preferiblemente según SEQ ID NO. 45.- Empleo de un compuesto farmacéutico según una de las reivindicaciones 1 a 4 para combatir enfermedades o estados originados por reacciones inmunológicas y formación patológica aumentada de anticuerpos, especialmente de autoanticuerpos.6.- Empleo según la reivindicación 5, caracterizado porque la enfermedad es esclerosis múltiple, lupus eritematoso sistémico, artritis reumatoide o una enfermedad que está acompañada por un número aumentado de células NK.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10157290A DE10157290A1 (de) | 2001-11-22 | 2001-11-22 | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590936A2 true CO5590936A2 (es) | 2005-12-30 |
Family
ID=7706571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04057552A CO5590936A2 (es) | 2001-11-22 | 2004-06-18 | Compuesto farmaceutico que contiene sfcyr iib o sfcyr iii |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20050002924A1 (es) |
| EP (1) | EP1446139B1 (es) |
| JP (1) | JP5414959B2 (es) |
| AT (1) | ATE409045T1 (es) |
| AU (1) | AU2002366200A1 (es) |
| CA (1) | CA2506068C (es) |
| CO (1) | CO5590936A2 (es) |
| DE (2) | DE10157290A1 (es) |
| ES (1) | ES2309238T3 (es) |
| WO (1) | WO2003043648A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1709073B1 (en) * | 2003-11-26 | 2011-08-10 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb) |
| US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| EP2914623B1 (en) | 2012-10-30 | 2016-12-28 | SuppreMol GmbH | A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease |
| AU2012244302B2 (en) * | 2012-10-31 | 2014-08-21 | Suppremol Gmbh | A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease |
| EP2796144A1 (en) | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Highly concentrated Formulations of soluble Fc receptors |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| JP6893223B2 (ja) * | 2013-10-16 | 2021-06-23 | ズプレモル ゲーエムベーハー | 医薬品組成物およびキット |
| CA2927263C (en) * | 2013-10-16 | 2022-12-13 | Suppremol Gmbh | Soluble fc gamma receptor for treatment of autoimmune bullous diseases |
| JP2018050616A (ja) | 2016-09-23 | 2018-04-05 | 東ソー株式会社 | 改良型組換えＦｃγＲＩＩ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1053255A4 (en) * | 1998-02-06 | 2003-01-02 | Ilexus Pty Ltd | THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS, AND USES THEREOF |
| EP1006183A1 (en) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| EP1201681A1 (en) * | 2000-10-30 | 2002-05-02 | Millennium Pharmaceuticals, Inc. | "Fail" molecules and uses thereof |
-
2001
- 2001-11-22 DE DE10157290A patent/DE10157290A1/de not_active Withdrawn
-
2002
- 2002-11-21 WO PCT/EP2002/013080 patent/WO2003043648A2/de active IP Right Grant
- 2002-11-21 AU AU2002366200A patent/AU2002366200A1/en not_active Abandoned
- 2002-11-21 JP JP2003545329A patent/JP5414959B2/ja not_active Expired - Lifetime
- 2002-11-21 DE DE50212814T patent/DE50212814D1/de not_active Expired - Lifetime
- 2002-11-21 CA CA2506068A patent/CA2506068C/en not_active Expired - Lifetime
- 2002-11-21 ES ES02803402T patent/ES2309238T3/es not_active Expired - Lifetime
- 2002-11-21 AT AT02803402T patent/ATE409045T1/de active
- 2002-11-21 EP EP02803402A patent/EP1446139B1/de not_active Expired - Lifetime
-
2004
- 2004-05-24 US US10/851,655 patent/US20050002924A1/en not_active Abandoned
- 2004-06-18 CO CO04057552A patent/CO5590936A2/es not_active Application Discontinuation
-
2008
- 2008-01-09 US US11/971,438 patent/US20080214459A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050002924A1 (en) | 2005-01-06 |
| CA2506068A1 (en) | 2003-05-30 |
| JP2005515981A (ja) | 2005-06-02 |
| ATE409045T1 (de) | 2008-10-15 |
| DE10157290A1 (de) | 2003-06-05 |
| WO2003043648A2 (de) | 2003-05-30 |
| ES2309238T3 (es) | 2008-12-16 |
| AU2002366200A8 (en) | 2003-06-10 |
| US20080214459A1 (en) | 2008-09-04 |
| EP1446139B1 (de) | 2008-09-24 |
| WO2003043648A3 (de) | 2004-01-08 |
| JP5414959B2 (ja) | 2014-02-12 |
| DE50212814D1 (de) | 2008-11-06 |
| EP1446139A2 (de) | 2004-08-18 |
| CA2506068C (en) | 2011-09-20 |
| AU2002366200A1 (en) | 2003-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL181473A (en) | Antibodies @ people @ against @@@ beta @@ preparations that include them and use them | |
| IL163629A0 (en) | Glutaminyl derivatives and pharmaceutical compositions containing the same | |
| WO2005002626A8 (en) | Therapeutic phosphonate compounds | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| CY1108649T1 (el) | Υποκατεστημενα αρυλπυραζολια ως παρασιτοκτονα | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| UA91815C2 (ru) | Выделенное антитело, которое специфически связывает gdf-8, и его применение | |
| SE9702001D0 (sv) | Novel compounds | |
| CY1110530T1 (el) | Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων | |
| PL1648925T3 (pl) | Środki obrazujące na bazie bicyklicznych peptydów | |
| CO5590936A2 (es) | Compuesto farmaceutico que contiene sfcyr iib o sfcyr iii | |
| TR200102338T2 (tr) | Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar. | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
| ATE406161T1 (de) | Kombination aus tenofovir, ritonavir und tmc114 | |
| BRPI0417950A (pt) | composições farmacêuticas | |
| AU2003291972A8 (en) | Pharmaceutical compositions comprising insulin and legends of insulin hexamer | |
| DE69918561D1 (de) | Modifizierte gruppen enthaltendes organosiloxan in pestizidzusammensetzungen | |
| MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
| SE0302755D0 (sv) | Novel compounds | |
| MXPA04000272A (es) | Derivados de 4-aminociclohexanol sustituidos. | |
| ATE270551T1 (de) | Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol | |
| WO2004043397A3 (en) | Compositions and methods for the treatment of rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |